An Investigational Study of Hydrocortisone

NCT01960530 | Completed Phase 1 Results

• 1 other identifier: Infacort 002
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

This study will investigate a new drug called Infacort®; a newly-developed immediate release formulation of a well-established drug called hydrocortisone. Hydrocortisone is used as a replacement treatment for people whose adrenal glands are not producing enough natural cortisol - a condition known as adrenal insufficiency. The study will assess how Infacort® acts once inside the body, by measuring cortisol and other hormone levels in the body, compared to already marketed hydrocortisone tablet and hydrocortisone intravenous (through the vein) injection. The population who are eligible to take part in the study are healthy male volunteers, aged between 18 and 60 years of age.

Conditions

Adrenal Insufficiency

Outcome Measures

Primary Outcomes (2)

• Maximum Serum Concentration (Cmax)

  Derived PK for Serum Cortisol: Maximum serum concentration (Cmax)

  Hourly from 0 to 24 hours

• AUC0-t

  Derived PK for Serum Cortisol: Area under the curve from 0-24 hours

  Hourly from 0 to 24 hours

Secondary Outcomes (4)

• Adverse Events (AEs)

  Days 1-2 during each Study Period

• Concentrations of Cortisol Binding Protein

  Blood samples on Day 1 and/or Day 2 of each Study Period

• Insulin Sensitivity Under Physiological Conditions and After Administration of Dexamethasone and Infacort®, Hydrocortisone Tablets and i.v Hydrocortisone.

  Blood samples on Day 1 and/or Day 2 of each Study Period

• PK and Metabolism of Cortisol

  Blood, urine & saliva samples on Day 1 and/or Day 2 of each Study Period

Study Arms (5)

Endogenous Cortisol

NO INTERVENTION

No Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.

Dexamethasone

OTHER

1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP

Other: Dexamethasone

Infacort®

EXPERIMENTAL

20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.

Drug: Hydrocortisone granules

Hydrocortisone Tablet

ACTIVE COMPARATOR

20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.

Drug: Hydrocortisone Tablet

i.v Hydrocortisone Injection

ACTIVE COMPARATOR

20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.

Drug: i.v. Hydrocortisone Injection

Interventions

Hydrocortisone granules DRUG

Multi-particulate granules

Also known as: Infacort

Infacort®

Hydrocortisone Tablet DRUG

Standard hydrocortisone tablets

Also known as: Commerical supply

Hydrocortisone Tablet

i.v. Hydrocortisone Injection DRUG

Standard hydrocortisone solution for intravenous injection

Also known as: Commerical supply

i.v Hydrocortisone Injection

Dexamethasone OTHER

Challenge agent

Also known as: Non-IMP

Dexamethasone

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male volunteers between 18 and 60 years of age, inclusive (at screening).
• Subjects with a Body Mass Index (BMI) of 21-28. Body Mass Index = Body weight (kg) / (Height (m))\*2.
• Subjects with no clinically significant abnormal serum biochemistry, haematology and urinalysis values within 14 days prior to Day 1 of Study Period 1.
• Subjects with a negative urinary drugs of abuse screen, determined within 14 days prior to Day 1 of Study Period 1. A positive alcohol test may be repeated at the discretion of the Investigator.
• Subjects with negative HIV and Hepatitis B and C results.
• Subjects with no clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 14 days prior to Day 1 of Study Period 1.
• Subjects with no clinically-significant deviation outside the normal ranges for blood pressure and pulse measurements.
• Subjects (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) and sexual partners must use effective contraception methods during the trial and for 3 months after the last dose, for example:
• Oral contraceptive + condom
• Intra-uterine device (IUD) + condom
• Diaphragm with spermicide + condom
• Subjects must be available to complete the study.
• Subjects must satisfy a medical examiner about their fitness to participate in the study.
• Subjects must provide written informed consent to participate in the study.

You may not qualify if:

• A clinically significant history of gastrointestinal disorder likely to influence drug absorption.
• Receipt of regular medication within 14 days prior to Day 1 of Study Period 1 (including high dose vitamins, dietary supplements or herbal remedies).
• Receipt of any vaccination within 14 days prior to Day 1 of Study Period 1.
• Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
• Presence of clinically significant infections (systemic fungal and viral infections, acute bacterial infections).
• Current or previous history of tuberculosis.
• A clinically significant history of previous allergy / sensitivity to Hydrocortisone and/or Dexamethasone.
• A clinically significant history or family history of psychiatric disorders/illnesses.
• A clinically significant history of drug or alcohol abuse.
• Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).
• Participation in a New Chemical Entity clinical study within the previous 4 months or a marketed drug clinical study within the previous 3 months. (N.B. The washout period between trials is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study)
• Subjects who have consumed more than 2 units of alcohol per day within seven (7) days prior to Day 1 of Study Period 1or have consumed any alcohol within the 48 hour period prior to Day 1 of Study Period 1.
• Donation of 450ml or more of blood within the previous 3 months.
• Subjects who smoke (or ex-smokers who have smoked within 6 months prior to Day 1 of Study Period 1).
• Subjects who work shifts (i.e. regularly alternate between days, afternoons and nights).

Sponsors & Collaborators

• Neurocrine UK Limited: lead
• Simbec Research: collaborator

Study Sites (1)

Simbec Research Limited

Merthyr Tydfil, CF48 4DR, United Kingdom

Location

MeSH Terms

Conditions

Adrenal Insufficiency

Interventions

Hydrocortisone; Dexamethasone

Condition Hierarchy (Ancestors)

Adrenal Gland Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Pregnenediones; Pregnenes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; 11-Hydroxycorticosteroids; Hydroxycorticosteroids; Adrenal Cortex Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; 17-Hydroxycorticosteroids; Pregnadienetriols; Pregnadienes; Steroids, Fluorinated

Results Point of Contact

• Title: Dr John Porter
• Organization: Diurnal Limited

info@diurnal.com

02920 682069

Study Officials

• Girish Sharma

  Simbec Research

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 6, 2013
• First Posted: October 10, 2013
• Study Start: October 1, 2013
• Primary Completion: November 1, 2014
• Study Completion: November 1, 2014
• Last Updated: April 26, 2022
• Results First Posted: April 13, 2017

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)